Form 4: Vor Biopharma's Chief Medical Officer Sells Shares Under 10b5-1 Trading Plan

Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., sold 14,645 shares of common stock at an average price of $1.39, according to a Form 4 filing with the SEC.

Summary

• On June 3, 2024, Eyal C. Attar, the Chief Medical Officer of Vor Biopharma Inc., sold 14,645 shares of the company's common stock.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2024.
• The shares were sold at a weighted average price of $1.39, with individual transaction prices ranging from $1.31 to $1.47.
• Following the transaction, Attar directly owns 96,063 shares of Vor Biopharma Inc.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares over a period of time while avoiding concerns about insider trading.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.

Key Dates